Literature DB >> 27821463

An urgent call to increase access to evidence-based opioid agonist therapy for prescription opioid use disorders.

M Eugenia Socías1, Keith Ahamad2.   

Abstract

Mesh：

Substances：

Year:  2016        PMID： 27821463      PMCID： PMC5135485          DOI： 10.1503/cmaj.160554

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  9 in total

Review 1.  Prescription opioid related misuse, harms, diversion and interventions in Canada: a review.

Authors:  Benedikt Fischer; Elena Argento
Journal:  Pain Physician       Date:  2012-07       Impact factor: 4.965

Review 2.  The prescription opioid and heroin crisis: a public health approach to an epidemic of addiction.

Authors:  Andrew Kolodny; David T Courtwright; Catherine S Hwang; Peter Kreiner; John L Eadie; Thomas W Clark; G Caleb Alexander
Journal:  Annu Rev Public Health       Date:  2015-01-12       Impact factor: 21.981

3.  Effective Canadian policy to reduce harms from prescription opioids: learning from past failures.

Authors:  Benedikt Fischer; Jürgen Rehm; Mark Tyndall
Journal:  CMAJ       Date:  2016-11-07       Impact factor: 8.262

Review 4.  Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence.

Authors:  Richard P Mattick; Courtney Breen; Jo Kimber; Marina Davoli
Journal:  Cochrane Database Syst Rev       Date:  2014-02-06

Review 5.  Medication-assisted treatment of opioid use disorder: review of the evidence and future directions.

Authors:  Hilary Smith Connery
Journal:  Harv Rev Psychiatry       Date:  2015 Mar-Apr       Impact factor: 3.732

6.  A Needs Assessment of the Number of Comprehensive Addiction Care Physicians Required in a Canadian Setting.

Authors:  Jasmine McEachern; Keith Ahamad; Seonaid Nolan; Annabel Mead; Evan Wood; Jan Klimas
Journal:  J Addict Med       Date:  2016 Jul-Aug       Impact factor: 3.702

Review 7.  Why buprenorphine is so successful in treating opiate addiction in France.

Authors:  M Fatseas; Marc Auriacombe
Journal:  Curr Psychiatry Rep       Date:  2007-10       Impact factor: 5.285

8.  Buprenorphine Maintenance for Opioid Dependence in Public Sector Healthcare: Benefits and Barriers.

Authors:  Laura G Duncan; Sonia Mendoza; Helena Hansen
Journal:  J Addict Med Ther Sci       Date:  2015-08-03

9.  Expansion of HAART coverage is associated with sustained decreases in HIV/AIDS morbidity, mortality and HIV transmission: the "HIV Treatment as Prevention" experience in a Canadian setting.

Authors:  Julio S G Montaner; Viviane D Lima; P Richard Harrigan; Lillian Lourenço; Benita Yip; Bohdan Nosyk; Evan Wood; Thomas Kerr; Kate Shannon; David Moore; Robert S Hogg; Rolando Barrios; Mark Gilbert; Mel Krajden; Reka Gustafson; Patricia Daly; Perry Kendall
Journal:  PLoS One       Date:  2014-02-12       Impact factor: 3.240
  9 in total
  10 in total

1.  The OPTIMA study, buprenorphine/naloxone and methadone models of care for the treatment of prescription opioid use disorder: Study design and rationale.

Authors:  M Eugenia Socias; Keith Ahamad; Bernard Le Foll; Ron Lim; Julie Bruneau; Benedikt Fischer; T Cameron Wild; Evan Wood; Didier Jutras-Aswad
Journal:  Contemp Clin Trials       Date:  2018-04-05       Impact factor: 2.226

2.  Density of low-barrier opioid agonist clinics and risk of non-fatal overdose during a community-wide overdose crisis: A spatial analysis.

Authors:  Ofer Amram; Eugenia Socías; Ekaterina Nosova; Thomas Kerr; Evan Wood; Kora DeBeck; Kanna Hayashi; Nadia Fairbairn; Julio Montaner; M J Milloy
Journal:  Spat Spatiotemporal Epidemiol       Date:  2019-07-04

3.  High-intensity cannabis use is associated with retention in opioid agonist treatment: a longitudinal analysis.

Authors:  Maria Eugenia Socías; Evan Wood; Stephanie Lake; Seonaid Nolan; Nadia Fairbairn; Kanna Hayashi; Hennady P Shulha; Seagle Liu; Thomas Kerr; M-J Milloy
Journal:  Addiction       Date:  2018-09-20       Impact factor: 6.526

4.  Cannabis use during methadone maintenance treatment for opioid use disorder: a systematic review and meta-analysis.

Authors:  Heather McBrien; Candice Luo; Nitika Sanger; Laura Zielinski; Meha Bhatt; Xi Ming Zhu; David C Marsh; Lehana Thabane; Zainab Samaan
Journal:  CMAJ Open       Date:  2019-11-19

5.  Trends in engagement in the cascade of care for opioid use disorder, Vancouver, Canada, 2006-2016.

Authors:  M Eugenia Socías; Evan Wood; Thomas Kerr; Seonaid Nolan; Kanna Hayashi; Ekaterina Nosova; Julio Montaner; M-J Milloy
Journal:  Drug Alcohol Depend       Date:  2018-05-29       Impact factor: 4.492

6.  Prevalence of Injecting Drug Use and Coverage of Interventions to Prevent HIV and Hepatitis C Virus Infection Among People Who Inject Drugs in Canada.

Authors:  Brendan Jacka; Sarah Larney; Louisa Degenhardt; Naveed Janjua; Stine Høj; Mel Krajden; Jason Grebely; Julie Bruneau
Journal:  Am J Public Health       Date:  2019-11-14       Impact factor: 9.308

7.  Opioid agonist treatment scale-up and the initiation of injection drug use: A dynamic modeling analysis.

Authors:  Charles Marks; Annick Borquez; Sonia Jain; Xiaoying Sun; Steffanie A Strathdee; Richard S Garfein; M-J Milloy; Kora DeBeck; Javier A Cepeda; Dan Werb; Natasha K Martin
Journal:  PLoS Med       Date:  2019-11-26       Impact factor: 11.069

8.  A rapid access to addiction medicine clinic facilitates treatment of substance use disorder and reduces substance use.

Authors:  David Wiercigroch; Hasan Sheikh; Jennifer Hulme
Journal:  Subst Abuse Treat Prev Policy       Date:  2020-01-13

9.  Convenience and comfort: reasons reported for using drugs alone among clients of harm reduction sites in British Columbia, Canada.

Authors:  Kristi Papamihali; Minha Yoon; Brittany Graham; Mohammad Karamouzian; Amanda K Slaunwhite; Vivian Tsang; Sara Young; Jane A Buxton
Journal:  Harm Reduct J       Date:  2020-11-23

Review 10.  Barriers and facilitators to opioid agonist therapy in rural and remote communities in Canada: an integrative review.

Authors:  Em M Pijl; Abeer Alraja; Elsie Duff; Carol Cooke; Stephen Dash; Nichole Nayak; Jesse Lamoureux; Ginette Poulin; Erin Knight; Ben Fry
Journal:  Subst Abuse Treat Prev Policy       Date:  2022-08-26
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.